Mathematical model to predict methotrexate elimination in children with acute lymphoblastic leukemia

1. Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, Bierings M, Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia. 2010;24(2):309-19 DOI: 10.1038/ leu.2009.25810.1038/leu.2009.25820016528Search in Google Scholar

2. Kampen KR. The discovery and early understanding of leukemia. Leuk Res. 2012;36(1):6-13. DOI: 10.1016/j. leukres.2011.09.028Search in Google Scholar

3. Mantadakis E, Cole PD, Kamen BA. High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use? Pharmacotherapy. 2005;25(5):748-55. DOI: 10.1592/phco.25.5.748.6358410.1592/phco.25.5.748.6358415899736Search in Google Scholar

4. Sterba J, Valík D, Bajciová V, Kadlecová V, Gregorová V, Mendelová D. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how? Neoplasma. 2005;52(6):456-63.Search in Google Scholar

5. Silverman LB, Stevenson KE, O’Brien JE, Asselin BL, Barr RD, Clavell L et al.: Long-term results of Dana- Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010;24(2):320-34. DOI: 10.1038/leu.2009.25310.1038/leu.2009.253282014120016537Search in Google Scholar

6. Veerman AJ, Hählen K, Kamps WA, Van Leeuwen EF, De Vaan GA, Solbu G, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol. 1996;14(3):911-8.10.1200/JCO.1996.14.3.9118622039Search in Google Scholar

7. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the Children’s Oncology Group. Leukemia. 2010;24(2):355-70. DOI: 10.1038/leu.2009.26110.1038/leu.2009.261430095920016527Search in Google Scholar

8. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):371-82. DOI: 10.1038/leu.2009.25210.1038/leu.2009.252282015920010620Search in Google Scholar

9. Matloub Y, Bostrom BC, Hunger SP, Stork LC, Angiolillo A, Sather H, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2011;118(2):243-51. DOI: 10.1182/ blood-2010-12-32290910.1182/blood-2010-12-322909313867921562038Search in Google Scholar

10. Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer S, Steuber CP, Camitta B. Intensification with intermediate- dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol. 2000;18(6):1285-94.10.1200/JCO.2000.18.6.128510715299Search in Google Scholar

11. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Soderhall S et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):345-54. DOI: 10.1038/leu.2009.25110.1038/leu.2009.25120010622Search in Google Scholar

12. Mitchell C, Richards S, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia. 2010;24(2):406-18. DOI: 10.1038/leu.2009.25610.1038/leu.2009.256282045220010621Search in Google Scholar

13. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. New Engl J Med. 1998;338(8):499-505. DOI: 10.1056/NEJM19980219338080310.1056/NEJM1998021933808039468466Search in Google Scholar

14. Mahoney DH, Shuster J, Nitschke R, Lauer SJ, Winick N, Steuber CP, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower- risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III Trial. J Clin Oncol. 1998;16(1):246-54.10.1200/JCO.1998.16.1.2469440749Search in Google Scholar

15. Camitta B, Mahoney D, Leventhat B, Lauer SJ, Shuster JJ, Adair S, et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 1994;12(7):1383-9.10.1200/JCO.1994.12.7.13838021728Search in Google Scholar

16. Camitta B, Leventhal B, Lauer S, Shuster JJ, Adair S, Casper J, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol. 1989;7(10):1539-44.10.1200/JCO.1989.7.10.15392778483Search in Google Scholar

17. Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24(2):265-84. DOI: 10.1038/leu.2009.25710.1038/leu.2009.25720010625Search in Google Scholar

18. Ahmed YA, Hasan Y. Prevention and Management of High Dose Methotrexate Toxicity. J Cancer Sci Ther 2013;5(3):106-12. DOI: 10.4172/1948-5956.100019310.4172/1948-5956.1000193Search in Google Scholar

19. Le Guellec C, Blasco H, Benz J, Hulin A. Therapeutic drug monitoring of methotrexate after its administrations in high-dose protocols. Therapie. 2010;65(3):163-9. DOI: 10.2515/therapie/201001610.2515/therapie/201001627392982Search in Google Scholar

20. Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol. 2010;30(6):570-81. DOI: 10.1016/j.semnephrol. 2010.09.005Search in Google Scholar

21. Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman P, et al. Clinical pharmacodynamics of high-dose methotrexate in childhood acute lymphocytic leukemia. Identification of a relation between concentration and effect. New Engl J Med. 1986;314(8):471-7. DOI: 10.1056/NEJM19860220314080310.1056/NEJM1986022031408033456079Search in Google Scholar

22. Panetta JC, Wall A, Pui CH, Relling MV, Evans WE. Methotrexate Intracellular Dispositionin Acute Lymphoblastic Leukemia.A Mathematical model of γ-Glutamyl Hydrolase Activity. Clin Cancer Res. 2002;8(7):2423-9.Search in Google Scholar

23. Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchinson R et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group (POG 9404). Blood. 2011;118(4):874-83. DOI: 10.1182/ blood-2010-06-29261510.1182/blood-2010-06-292615329243721474675Search in Google Scholar

24. Bertino JR, Goker E, Gorlick R, Li WW, Banerjee D. Resistance mechanisms to methotrexate in tumors. Oncologist. 1996;1(4):223-6.10.1634/theoncologist.1-4-223Search in Google Scholar

25. Matherly LH, Taub JW. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Leuk Lymphoma. 1996;21(5-6):359-68. DOI: 10.3109/1042819960909343310.3109/10428199609093433Search in Google Scholar

26. Gorlick R, Goker E, Trippett T, Watham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. New Engl J Med. 1996;335(14):1041-8. DOI: 10.1056/ NEJM19961003335140810.1056/NEJM199610033351408Search in Google Scholar

27. Farrow AC, Buchanan GR, Zwiener RJ, Bowman WP, Winick NJ. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 1997;15(4):1560-6.10.1200/JCO.1997.15.4.1560Search in Google Scholar

28. Moe PJ, Holen A.: High-dose methotrexate in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 2000;17(8):615-22. DOI: 10.1080/0888001005021132110.1080/08880010050211321Search in Google Scholar

29. Maiquma T, Hayashi Y, Ueshima S, Kaji M, Eqawa T, Chayama T, et al. Relationship between oral mucositis and high-dose methotrexate in pediatric acute lymphoblastic leukemia. Int J Clin Pharmacol Ther. 2008;46(11):584-90. DOI: 10.5414/CPP4658410.5414/CPP46584Search in Google Scholar

30. Xu WQ, Tang YM, Fanq CQ, Song H, Shi SW, Yang SL, et al. Study on elimination delay in high-dose methotrexate in children with acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2005;26(1):15-8.Search in Google Scholar

31. Isoda T, Ito S, Kajiwara M, Nagasawa M. Successful high-dose methotrexate therapy in a patient with acute lymphoblastic leukemia who developed acute renal failure during initial treatment. Pediatr Int. 2007;49(6):1018-9. DOI: 10.1111/j.1442-200X.2007.02461.x10.1111/j.1442-200X.2007.02461.xSearch in Google Scholar

32. Perez-Verdia A, Angulo F, Hardwicke FL, Nugent KM. Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy. 2005:25(9):1271-6. DOI: 10.1592/phco.2005.25.9.127110.1592/phco.2005.25.9.1271Search in Google Scholar

33. Joannon P, Oviedo I, Campbell M, Tordecilla J. High dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer. 2004;43(1):17-22. DOI: 10.1002/ pbc.2003210.1002/pbc.20032Search in Google Scholar

34. Borsi JD, Moe PJ. Systemic Clearance of Methotrexate in the Prognosis of Acute Lymphoblastic Leukemia in Children. Cancer. 1987;60(12):3020-4. DO I:2/1097-0142(19871215)60:12<3020::AID-CNCR2820601227> 3.0.CO;2-010.1002/1097-0142(19871215)60:12<3020::AID-CNCR2820601227>3.0.CO;2-0Search in Google Scholar

35. Hein DW, Doll MA. Accuracy of various NAT 2 SNP genotyping panelsto infer rapid, intermediateand slow acetylator phenotypes. Pharmacogenomics. 2012;13(1):31-41. DOI: 10.2217/pgs.11.122 10.2217/pgs.11.122Search in Google Scholar